🧠 Food for thought

Implications, context, and why it matters.

OMN6’s Phase II trial targets a narrow population where standard antibiotics fail

• Phase II enrolls 54 patients with hospital-acquired or ventilator-associated pneumonia caused by Acinetobacter baumannii complex (ABC) 1, a pathogen with mortality about 40% 2
• Unmet need persists with carbapenem (a last-line beta-lactam antibiotic class) resistance in ABC up to 80% in some regions 2, while colistin is a polymyxin that reaches lungs poorly and has toxicities 2
• OMN6’s minimum inhibitory concentration at which 50% of isolates are inhibited (MIC50) against A. baumannii fell four-fold in the presence of lung surfactant (the protective fluid lining the lungs) 3, which may help in pneumonia where colistin has poor pulmonary distribution
• Small sample size makes any comparison to sulbactam-durlobactam, a beta-lactam/beta-lactamase inhibitor for drug-resistant A. baumannii, premature 2. ATTACK, the Phase III trial, met non-inferiority versus colistin with lower mortality trends 2

Peptide contract development and manufacturing organization (CDMO) suppliers with antimicrobial peptide (AMP) manufacturing expertise see near-term work

• The $25 million funds manufacturing scale-up for OMN6, a 40-amino-acid cyclic peptide that needs specialized production 3
• CDMOs offering current Good Manufacturing Practice (cGMP) peptide synthesis, sterile injectable fill-finish (aseptic vialing), and lyophilization (freeze-drying) can win work as Omnix advances from Phase II 4
• Antimicrobial peptides (AMPs) form a newer class with manufacturing steps unlike small-molecule antibiotics, giving suppliers with AMP experience an edge 3
• Corden Pharma, a CDMO with integrated Active Pharmaceutical Ingredient (API)-to-drug-product peptide services using solid-phase and liquid-phase synthesis at multi-ton scale, fits Omnix’s likely commercial needs 5